Taysha Gene Therapies, Inc.
TSHA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TSHA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TSHA
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic central nervous system diseases, with its lead candidate TSHA-102 targeting Rett syndrome.
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.88B
Cash Runway
33.9 moLead Asset
TSHA-102 (Phase 3)
Next Catalyst
Phase3_Topline · Jun 1, 2031Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 2 catalysts for Taysha Gene Therapies, Inc..
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic central nervous system diseases, with its lead candidate TSHA-102 targeting Rett syndrome.
- Lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies addressing the genetic root cause [sec_mda · as of 2025-02-26].
- As of June 30, 2026, the company had cash and equivalents of $455.4 million, an accumulated deficit of $800.3 million, and no revenue from product sales [sec].
- The company expects to continue incurring significant operating losses and will need substantial additional funding to advance its pipeline and clinical trials [sec_mda · as of 2026-08-11].
- In November and December 2025, the company raised $48.4 million in net proceeds through an at-the-market offering of common stock [sec_mda · as of 2026-08-11].
- The company's most significant purchase commitments include approximately $39.3 million in cancellable purchase commitments as of June 30, 2026 [sec_mda · as of 2026-08-11].
What works
- Taysha has a singular focus on developing transformative gene therapies for severe monogenic CNS diseases, addressing high unmet medical needs [sec_mda · as of 2025-02-26].
- The company raised $215.6 million in net proceeds from a May 2025 offering, providing a substantial cash runway to support ongoing clinical development [sec_mda · as of 2025-08-12].
- TSHA-102 targets Rett syndrome, a condition with no approved disease-modifying therapies that address the genetic root cause, representing a significant market opportunity [sec_mda · as of 2025-02-26].
What to weigh
- Taysha has not generated any revenue from product sales and does not expect to generate significant revenue for at least the next few years [sec_mda · as of 2026-08-11].
- The company has an accumulated deficit of $800.3 million as of June 30, 2026, and expects to continue incurring significant operating losses [sec_mda · as of 2026-08-11].
- Taysha will require substantial additional funding to support its operations, and if unable to raise capital on favorable terms, it may need to delay or reduce its programs [sec_mda · as of 2026-08-11].
- The company's lead candidate TSHA-102 is still in clinical development, and there is no guarantee of regulatory approval or commercial success [sec_mda · as of 2025-02-26].
From the filings
Quoted directly from source documents.
Taysha is a clinical-stage company focused on AAV-based gene therapies for CNS diseases.
“We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS.”
SEC MD&A · February 26, 2025
TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder.
“Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.”
SEC MD&A · February 26, 2025
As of June 30, 2026, the company had an accumulated deficit of $800.3 million.
“As of June 30, 2026, we had an accumulated deficit of $800.3 million.”
SEC MD&A · August 11, 2026
The company raised $48.4 million in net proceeds from stock sales in late 2025.
“In November and December 2025, we sold 10,230,186 shares of common stock under the Amended Sales Agreement and received $48.4 million in net proceeds.”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2031-06-01 · Phase3_Topline — Phase 3 Topline: ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary — Topline data from the Phase 3 ASPIRE study of TSHA-102 in Rett syndrome will be a key efficacy and safety readout.
- 2031-06-01 · Phase3_Topline — Phase 3 Topline: An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dos — Topline data from the Phase 1/2/3 study of TSHA-102 will provide additional safety and efficacy information.
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — Taysha has no approved products and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-08-11].
- Need for additional funding — The company will require substantial additional capital to fund its operations, and failure to raise it may force program delays or reductions [sec_mda · as of 2026-08-11].
- Clinical and regulatory uncertainty — TSHA-102 is still in clinical trials, and there is no guarantee of successful development or regulatory approval [sec_mda · as of 2025-02-26].
- Dependence on single lead candidate — The company's pipeline is heavily reliant on TSHA-102, with limited diversification in later-stage programs [sec_mda · as of 2025-02-26].
What to watch
- Phase 3 topline data from the ASPIRE study for TSHA-102, expected around June 2031 [catalyst_timeline].
- Updates on the company's ability to raise additional capital or secure partnerships to extend its cash runway [sec_mda · as of 2026-08-11].
- Progress in preclinical and discovery programs that could diversify the pipeline [sec_mda · as of 2026-08-11].
- Any regulatory milestones or interactions with health authorities regarding TSHA-102 [sec_mda · as of 2025-02-26].
Sources: SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Taysha Gene Therapies, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Taysha Gene Therapies, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
33.9 months
D/E 0.21 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~1736d
0 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
191
Total value held
$1.09B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 23,555,648 | $105.3M |
| goldman sachs group inc | 22,369,645 | $100.0M |
| vanguard capital management llc | 20,463,004 | $91.5M |
| blackrock, inc. | 18,365,608 | $82.1M |
| morgan stanley | 17,965,371 | $80.3M |
| fmr llc | 14,321,255 | $64.0M |
| rtw investments, lp | 13,680,248 | $61.2M |
| state street corp | 11,209,078 | $50.1M |
| octagon capital advisors lp | 8,859,911 | $39.6M |
| siren, l.l.c. | 8,829,913 | $39.5M |
Showing top 10 of 191 institutional holders of Taysha Gene Therapies, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 13.8%
- Days to cover
- 12.8
- Shares short
- 38,915,976
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TSHA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic central nervous system diseases, with its lead candidate TSHA-102 targeting Rett syndrome.
What is Taysha Gene Therapies, Inc.'s lead drug candidate?
Taysha Gene Therapies, Inc.'s most advanced tracked candidate is TSHA-102 (Phase 3) for Rett Syndrome.
What is Taysha Gene Therapies, Inc.'s next catalyst?
Taysha Gene Therapies, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary " — expected June 1, 2031.
Who is the CEO of Taysha Gene Therapies, Inc.?
Mr. Sean P. Nolan is the chief executive officer of Taysha Gene Therapies, Inc. (TSHA).
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc. (TSHA) is headquartered in Dallas, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.